Alfonso Calvo

Summary

Affiliation: University of Navarra
Country: Spain

Publications

  1. Exposito F, Villalba M, Redrado M, de Aberasturi A, Cirauqui C, Redin E, et al. Targeting of TMPRSS4 sensitizes lung cancer cells to chemotherapy by impairing the proliferation machinery. Cancer Lett. 2019;453:21-33 pubmed publisher
    ..These results show that TMPRSS4 can be considered as a novel target in NSCLC, whose inhibition increases chemosensitivity. ..
  2. Manrique I, Nguewa P, Bleau A, Nistal Villán E, Lopez I, Villalba M, et al. The inhibitor of differentiation isoform Id1b, generated by alternative splicing, maintains cell quiescence and confers self-renewal and cancer stem cell-like properties. Cancer Lett. 2015;356:899-909 pubmed publisher
    ..Our results show that Id1b maintains cells in a quiescent state and promotes self-renewal and CSC-like features. On the contrary, Id1a promotes cell proliferation. ..
  3. Agliano A, Calvo A, Box C. The challenge of targeting cancer stem cells to halt metastasis. Semin Cancer Biol. 2017;44:25-42 pubmed publisher
    ..In particular, we consider CSC-targeting agents for which there is experimental evidence of anti-metastatic properties and which may have potential to eventually limit relapse and impede metastasis in patients. ..
  4. Villalba M, López L, Redrado M, Ruiz T, de Aberasturi A, de la Roja N, et al. Development of biological tools to assess the role of TMPRSS4 and identification of novel tumor types with high expression of this prometastatic protein. Histol Histopathol. 2017;32:929-940 pubmed publisher
    ..Future studies should determine the clinical value of assessing TMPRSS4 levels in different types of lung cancer. ..
  5. Diaz R, Nguewa P, Parrondo R, Perez Stable C, Manrique I, Redrado M, et al. Antitumor and antiangiogenic effect of the dual EGFR and HER-2 tyrosine kinase inhibitor lapatinib in a lung cancer model. BMC Cancer. 2010;10:188 pubmed publisher
    ..In addition, tumors from lapatinib-treated mice showed a dramatic reduction in angiogenesis (P < 0.0001). Overall, these data suggest that lapatinib may be a clinically useful agent for the treatment of lung cancer. ..
  6. de Aberasturi A, Redrado M, Villalba M, Larzabal L, Pajares M, Garcia J, et al. TMPRSS4 induces cancer stem cell-like properties in lung cancer cells and correlates with ALDH expression in NSCLC patients. Cancer Lett. 2016;370:165-76 pubmed publisher
    ..These results show that TMPRSS4, in addition to inducing EMT, can also promote CSC features in lung cancer; therefore, CSC-targeting drugs could be an appropriate treatment for TMPRSS4+ tumors. ..
  7. Villalba M, Evans S, Vidal Vanaclocha F, Calvo A. Role of TGF-? in metastatic colon cancer: it is finally time for targeted therapy. Cell Tissue Res. 2017;370:29-39 pubmed publisher
    ..We provide up-to-date information of these therapies, which are currently in preclinical or clinical trials. ..
  8. Mari Alexandre J, Díaz Lagares A, Villalba M, Juan O, Crujeiras A, Calvo A, et al. Translating cancer epigenomics into the clinic: focus on lung cancer. Transl Res. 2017;189:76-92 pubmed publisher
    ..We envision that epigenomics will translate into the clinical field and will have an impact on lung cancer diagnosis/prognosis and treatment. ..
  9. Bleau A, Redrado M, Nistal Villán E, Villalba M, Exposito F, Redin E, et al. miR-146a targets c-met and abolishes colorectal cancer liver metastasis. Cancer Lett. 2018;414:257-267 pubmed publisher
    ..Our results document a new mechanism for c-met regulation in CLM and highlight the crucial role of miR-146a in suppressing tumorigenesis. ..